Pharmaceuticals & Therapeutics

NurExone appoints Eyal Gabbai, a healthcare and finance heavyweight, to its board, signaling a strategic pivot from R&D to market execution for its therapies.

With its third Forbes nod, Jackson Healthcare's mix of strategic growth, tech, and culture reveals a model for navigating the healthcare crisis.

Leaders from The ROOT Brands attended the WEF, sparking debate on being 'biologically strong' in an AI-driven world. What does this mean for our future?

A landmark deal revives a Greek arms factory, creating hundreds of jobs and aiming to solve Europe's critical ammunition shortage amid rising tensions.

ALX Oncology data shows CD47 levels predict response to evorpacept, offering new hope for heavily pretreated patients in a crowded therapeutic landscape.

Ruxolitinib cream's landmark approval in China marks a new era for vitiligo treatment, impacting patients, markets, and regulatory policy.

A $10M investment from pharma giant Dr. Reddy’s validates Coya Therapeutics' novel ALS drug, funding the path to commercial-scale manufacturing.

After Amgen steps back, Kyowa Kirin takes full control of its promising atopic dermatitis drug, rocatinlimab, betting on its unique science.

With stronger Phase 2 data for its ATH434 drug and a healthy cash reserve, Alterity Therapeutics is preparing for a pivotal trial and seeking partners.

Lexicon Pharmaceuticals raised nearly $95 million to fund its drug pipeline, but the move sent its stock plunging as investors weighed future promise against immediate dilution.

After teetering on the brink, Poxel SA has secured court approval for a complex recovery plan, offering a lifeline for its innovative metabolic drug pipeline.

New data on Idorsia's lucerastat reveals potential to slow kidney decline in Fabry disease, offering a new path for an oral, genotype-independent therapy.

A groundbreaking implantable cell therapy shows consistent, positive results for a debilitating complication of Crohn's disease, paving an expedited path to market.

A family alleges a 75-year-old woman died from a septic wound after a rehab facility failed to provide basic care, sparking a major wrongful death lawsuit.

A new report warns US drug price controls could mirror Canada's struggles, delaying access to new medicines. Is America trading innovation for affordability?

A new center in China is using a novel drug and special policies to offer hope against NUT carcinoma, a rare and deadly cancer affecting the young.

The Spanish pharma giant secures approval for the first oral antibiotic specifically for acne in China, targeting a multi-billion dollar dermatology market.

A new partnership gives Texas small business employees free access to a clinically proven virtual program aimed at reversing Type 2 diabetes, not just managing it.

A single-injection radiotherapy for canine arthritis is proven safe and effective in a new study, changing how vets and owners manage chronic joint pain.

As its promising prostate cancer drug nears Phase 3, Convergent Therapeutics hires a new CPO to build the team for its next critical growth phase.